DNTH Stock Analysis: Dianthus Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 4.305m USD | 12M Return: 123% | US2528281080 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 74.9M
Warnings
Tailwinds
No distinct edge detected
Seasonality 8.3 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Dianthus Therapeutics (NASDAQ: DNTH) is a U.S.-based, clinical-stage biotechnology company founded in 2019 and headquartered in New York. It focuses on developing therapies for patients with severe autoimmune diseases, with a pipeline led by claseprubart, a monoclonal antibody engineered for extended half-life and selective inhibition of the active C1s complement protein, and DNTH212, a bifunctional fusion protein that reduces Type 1 interferon production through BDCA2 targeting on plasmacytoid dendritic cells while suppressing B cell function via BAFF/APRIL inhibition. The company went public in September 2023 and is classified within the Health Care sector under the Biotechnology sub-industry.
As a clinical-stage biotech without approved products, Dianthus is pre-revenue and typically funds operations through equity offerings and capital markets activity, a common structure for development-stage companies in this sector. The complement and autoimmune disease space in which it operates is competitive, with several larger pharmaceutical and biotech firms also pursuing C1s and related complement targets.
- Claseprubart Phase 2 data in CIDP and HSCT-TMA advances pipeline
- DNTH212 dual-mechanism pDC inhibitor enters clinical development
- Cash position funds operations with no near-term dilutive financing pressure
| Net Income: -29.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.13 > 0.02 and ΔFCF/TA 17.94 > 1.0 |
| NWC/Revenue: 45.3k% < 20% (prev 5.02k%; Δ 40.3k% < -1%) |
| CFO/TA -0.13 > 3% & CFO -155.4m > Net Income -29.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 26.10 > 1.5 & < 3 |
| Outstanding Shares: last quarter (56.0m) vs 12m ago 56.41% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.25% > 50% (prev 1.49%; Δ -1.24% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.71 (Total Current Assets 897.5m - Total Current Liabilities 34.4m) / Total Assets 1.21b |
| B: -0.35 (Retained Earnings -427.8m / Total Assets 1.21b) |
| C: -0.04 (EBIT TTM -29.9m / Avg Total Assets 769.7m) |
| D: 28.42 (Book Value of Equity 1.17b / Total Liabilities 41.2m) |
| Altman-Z'' = 33.09 = AAA |
| DSRI: 3.0 (Receivables 106k/39.0k, Revenue 1.90m/4.85m) |
| GMI: 0.95 (GM 91.22% / 96.01%) |
| AQI: 1.39 (AQ_t 0.26 / AQ_t-1 0.19) |
| SGI: 0.39 (Revenue 1.90m / 4.85m) |
| TATA: 0.10 (NI -29.9m - CFO -155.4m) / TA 1.21b) |
| Beneish M = -1.62 (Cap -4..+1) = CCC |
As of October 22, 2026, the stock is trading at USD 78.10 with a total of 1,194,113 shares traded. Over the past week, the price has changed by +4.47%, over one month by -19.04%, over three months by -26.13% and over the past year by +122.95%.
Current recommended Stop Loss: 72.50 (which is 7.2% or 1.2 ATR below the current price).
Dianthus Therapeutics has received a consensus analysts rating of 4.94. Therefore, it is recommended to buy DNTH.
- StrongBuy: 16
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 140.8 | 80.3% |
P/S = 2313.4624
P/B = 4.4556
Revenue TTM = 1.90m USD
EBIT TTM = -29.9m USD
EBITDA TTM = -29.5m USD
Long Term Debt = 913k USD (estimated: total debt 1.29m - short term 374k)
Short Term Debt = 374k USD (from shortTermDebt, last quarter)
Debt = 1.29m USD (from shortLongTermDebtTotal, last quarter) (leases 1.29m already included)
Net Debt = -885.5m USD (calculated: Debt 1.29m - CCE 886.8m)
Enterprise Value = 3.42b USD (4.30b + Debt 1.29m - CCE 886.8m)
Interest Coverage Ratio = unknown (Ebit TTM -29.9m / Interest Expense TTM 0.0)
EV/FCF = -21.96x (Enterprise Value 3.42b / FCF TTM -155.7m)
FCF Yield = -4.55% (FCF TTM -155.7m / Enterprise Value 3.42b)
FCF Margin = -8.18k% (FCF TTM -155.7m / Revenue TTM 1.90m)
Net Margin = -1.57k% (Net Income TTM -29.9m / Revenue TTM 1.90m)
Gross Margin = unknown ((Revenue TTM 1.90m - Cost of Revenue TTM 76.0k) / Revenue TTM)
Tobins Q-Ratio = 2.82 (Enterprise Value 3.42b / Total Assets 1.21b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 1.29m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -23.6m (EBIT -29.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 26.10 (Total Current Assets 897.5m / Total Current Liabilities 34.4m)
Debt / Equity = 0.00 (Debt 1.29m / totalStockholderEquity, last quarter 1.17b)
Debt / EBITDA = 29.99 (negative EBITDA) (Net Debt -885.5m / EBITDA -29.5m)
Debt / FCF = 5.69 (negative FCF - burning cash) (Net Debt -885.5m / FCF TTM -155.7m)
Total Stockholder Equity = 853.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -3.89% (Net Income -29.9m / Total Assets 1.21b)
RoE = -3.51% (Net Income TTM -29.9m / Total Stockholder Equity 853.3m)
RoCE = -3.50% (EBIT -29.9m / Capital Employed (Equity 853.3m + L.T.Debt 913k))
RoIC = -2.00% (negative operating profit) (NOPAT -23.6m / Invested Capital 1.18b)
WACC = 8.57% (E(4.30b)/V(4.31b) * Re(8.57%) + D(1.29m)/V(4.31b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 8.57% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 87.22 | Cagr: 41.48%
[DCF] Fair Price = unknown (Cash Flow -155.7m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.16 | # QB: 0
Revenue Correlation: -47.23 | Revenue CAGR: -22.80% | SUE: 0.63 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.95 | Chg30d=+6.99% | Revisions=+17% | Analysts=10
EPS current Year (2026-12-31): EPS=-3.81 | Chg30d=+2.70% | Revisions=+17% | GrowthEPS=+9.2% | GrowthRev=-8.2%
EPS next Year (2027-12-31): EPS=-4.61 | Chg30d=+2.79% | Revisions=+17% | GrowthEPS=-20.9% | GrowthRev=-5.1%
[Analyst] Revisions Ratio: +25% (up=6, down=3)